Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy...
-
Upload
payton-roger -
Category
Documents
-
view
218 -
download
1
Transcript of Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy...
![Page 1: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/1.jpg)
Pharmaceutical aspects of the development of anti-infectives
Dr Jeffrey R Edwards
Infection Therapy Area
AstraZeneca
![Page 2: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/2.jpg)
Why develop a new anti-infective agent? The infrastructure required , competition for resources Really ‘new’, another variant or ‘a compound too far’? Discovery and development.
![Page 3: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/3.jpg)
Why develop a new anti-infective agent? The infrastructure required , competition for resources Really ‘new’, another variant or ‘a compound too far’? Discovery and development.
![Page 4: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/4.jpg)
RESISTANCE
![Page 5: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/5.jpg)
• Bacterial resistance is now a high-profile issue for Governments, International bodies and the press
But .......
• there always has been and there always will be bacterial resistance to anti-microbials
• we probably don’t really know how to select a dosing regimen and use agents optimally
• we don’t help by being imprecise with terminology: we fail to distinguish between ‘mechanisms of resistance’ and therapeutic failure
• we rarely identify unusual events or show diminished susceptibility: breakpoints have a lot to answer for!
Some observations .........
![Page 6: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/6.jpg)
• resistance varies between countries
• within hospitals, ITUs have the problems
• resistance is seen in the community.
![Page 7: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/7.jpg)
Some highly publicised resistance problems
• multi-resistant staphylococci
• penicillin-resistant pneumococci
• macrolide-resistant group-A streptococci
• VAN-R enterococci
• Corynebacterium jeikeium
• Mycobacterium tuberculosis
• Enterobacteriaceae
•ESBLs, notably in Klebsiella
• chromosomal -lactamases
•Enterobacter, Citrobacter etc
•Salmonella typhi
•Shigella dysenteriae
• Pseudomonas aeruginosa
• Burkholderia cepacia
• Stenotrophomonas maltophilia
![Page 8: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/8.jpg)
Limited choice of therapy
• penicillin- and macrolide-resistant pneumococci
• macrolide-resistant Group A streptococci
• ESBL bearing Enterobacteriaceae
• Enterobacteriaceae over-expressing chromosomal lactamases
• Pseudomonas aeruginosa
• Pseudomonas spp.
• Acinetobacter spp.
• Burkholderia cepacia
• Stenotrophomonas maltophilia
![Page 9: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/9.jpg)
![Page 10: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/10.jpg)
Untreatable bacteria
• multi-resistant staphylococci
• vancomycin-resistant enterococci
•Corynebacterium jeikeium
•Mycobacterium tuberculosis
![Page 11: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/11.jpg)
![Page 12: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/12.jpg)
Summary
• There are a relatively small number of untreatable bacteria
• There is a reduction in the choice of agents to use
• There is an unquantified issue relating to undetected diminished susceptibility
Therefore, new agents are needed !
![Page 13: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/13.jpg)
Why develop a new anti-infective agent? The infrastructure required , competition for resources Really ‘new’, another variant or ‘a compound too far’? Discovery and development.
![Page 14: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/14.jpg)
The infrastructureTherapy areas
• GI
• Cancer
• CNS
• CVS
• Pain
• Respiratory
• Infection
![Page 15: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/15.jpg)
The infrastructureTherapy areas
• GI
• Cancer
• CNS
• CVS
• Pain
• Respiratory
• Infection
Commercial activities
• Market research
• Quantifying opportunities
• Preparing for launch
• Launching/ selling
• Life cycle
![Page 16: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/16.jpg)
The infrastructureTherapy areas
• GI
• Cancer
• CNS
• CVS
• Pain
• Respiratory
• Infection
Development Depts.
• Large scale synthesis
• Formulation
• Manufacture
• Safety evaluation
• Clinical evaluation
• Regulatory
• Intellectual Property
Commercial activities
• Market research
• Quantifying opportunities
• Preparing for launch
• Launching / selling
• Life cycle
![Page 17: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/17.jpg)
The infrastructureTherapy areas
Infection
Development Depts
• Large scale synthesis
• Formulation
• Manufacture
• Safety evaluation
• Clinical evaluation
• Regulatory
• Intellectual property
Commercial activities
• Market research
• Quantifying opportunities
• Preparing for launch
• Launching and selling
• Life cycle
![Page 18: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/18.jpg)
Why develop a new anti-infective agent? The infrastructure required , competition for resources Really ‘new’, another variant or ‘a compound too far’? Discovery and development.
![Page 19: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/19.jpg)
A compound too far .............. ??
![Page 20: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/20.jpg)
-lactam antibiotics
![Page 21: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/21.jpg)
Nucleus
COOH
penem
N
S
O
H H
COOH
carbapenem
NO
H H
SNH
penicillin
NO
COOH
CH3
CH3
COOH
carbacephem
N
NH
OCOOH
cephalosporin
N
NH S
O
![Page 22: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/22.jpg)
Outer membrane
-Lactamase
Cytoplasmic membrane
Periplasmic space
Peptidoglycan
![Page 23: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/23.jpg)
Penicillins
benzylpenicillin / methicillin or oxacillin ampicillin / amoxycillin amoxycillin + clavulanate piperacillin piperacillin + tazobactam
Continuing problem of instability to -lactamases
![Page 24: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/24.jpg)
Cephalosporins
cefotaxime ceftriaxone ceftazidime cefepime / cefpirome
Problems of emergence of resistance, commonly -lactamases
![Page 25: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/25.jpg)
Carbapenems
![Page 26: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/26.jpg)
Structures of meropenem and imipenem + cilastatin
HOH
CH3
N
CONCH3
CH3
CH3
S
COOHO
H
NH
Meropenem
NH
Imipenem
NHCH
HOH
CH3
NS
COOHO
H
NH
SCOOH
NH2
OCOOH
Cilastatin
+
![Page 27: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/27.jpg)
Gaps in the spectrum of carbapenems
• methicillin-resistant staphylococci• some enterococci• some pseudomonads• ? B. cepacia• S. maltophilia
Newer molecules have exhibited toxicities not normally associated with lactams !!
![Page 28: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/28.jpg)
Quinolones
![Page 29: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/29.jpg)
Quinolones
• what has been ‘added’ since ciprofloxacin?• what will be added in the future?
• toxicity seen in
• temafloxacin• trovafloxacin• grepafloxacin• moxifloxacin• clinafloxicin• others struggling?
![Page 30: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/30.jpg)
Really new ...........
genome-based target discovery
![Page 31: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/31.jpg)
Model GenomesE. coli or S. cerevisiae
essential for viability
selectivity
spectrum
technical feasibility
TARGETS
Filters
literature reviewknowledge/experience
literature reviewknowledge/experience
literature reviewknowledge/experience
Antibacterial Antifungal
![Page 32: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/32.jpg)
Genome-based target discovery
• new targets do not guarantee new drugs• new targets have no ‘history’ • how will they be viewed by Regulatory agencies ?• how will you, the user, feel about a series of agents about which you know nothing ?
• will you reserve them as drugs to use last ? • diversity in the compound-collection is very important when screening.
![Page 33: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/33.jpg)
Why develop a new anti-infective agent? The infrastructure required , competition for resources Really ‘new’, another variant or ‘a compound too far’? Discovery and development.
![Page 34: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/34.jpg)
World market for anti-infectives is ~$US 37 billion
![Page 35: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/35.jpg)
• World market for anti-infectives is ~$US 37 billion
• anti-bacterials is ~$ 24 bn
• hospital anti-bacterials is $ 8.5 bn
• serious hospital anti-bacterials is $ 2.5 bn
• s/h respiratory is $ 0.7 - 1 bn.
![Page 36: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/36.jpg)
The cost of developing a multi-indication anti-bacterial is
~ $US 400 - 600 million
![Page 37: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/37.jpg)
No company can do everything, so .......
Focus research in
• selected areas
• against drug-profiles which are based on
• medical need and
• commercial attractiveness.
![Page 38: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/38.jpg)
New agents will come from genome-based programmes
The process
Select and validate a target
design a 500,000 HTS
identify hits and ‘sanitise’
progress chemistry
select lead series
optimise leads
select candidate(s) for development.
With attrition at every stage, you’r lucky to do this in 5 years.
![Page 39: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/39.jpg)
Evaluating candidates for development
(assume you have in vitro and in vivo activity)
• perform extensive laboratory studies on short-list• pre-screen for toxicity• assess pK in animals and model for human kinetics• can it be manufactured?• select candidate• After these several years, is it still competitive?
If this is a new target and a new chemical series therewill be no precedent upon which to make judgements.
![Page 40: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/40.jpg)
Developing a new agent (1)
• be sure of
• toxicological support for the compound• a secure route of manufacture• patent protection of the molecule and its route of synthesis
• secure resources for
• the pre-clinical phase• the ‘proof of concept testing’ • the complete clinical package to support both Regulatory and launch requirements.
![Page 41: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/41.jpg)
Developing a new agent (2)
• decide upon which indications to trial, globally• narrow-spectrum does not mean narrow indications
• select and access suitable clinical trial centers• many are not acceptable to major Agencies
• co-ordinate microbiology, kinetics, clinical programme and all other components of a regulatory dossier
• plan launches in anticipation of acceptable licenses
• file your dossier(s) and be prepared to interact with and respond rapidly to questions
• hopefully, launch in first territories and prepare for others.
![Page 42: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/42.jpg)
BUT .................................
you can be well through the process when things change!
• IDSA guidelines
• new problems with an established class may result in changes in Regulatory requirements
• ESBLs had not been documented when cefepime was discovered.
![Page 43: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/43.jpg)
Why develop a new anti-infective agent? The infrastructure required , competition for resources Really ‘new’, another variant or ‘a compound too far’? Discovery and development.
![Page 44: Pharmaceutical aspects of the development of anti-infectives Dr Jeffrey R Edwards Infection Therapy Area AstraZeneca.](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649c725503460f9492367f/html5/thumbnails/44.jpg)
Summary
• the process is increasingly complex and expensive
• we all agree that new anti-infective agents are required
• conversely, the difficulty in discovering and developing new molecules in not appreciated fully
• some of the ‘problems’ and ‘needs’ require precise definition
• new agents will emerge only with the co-operation of providers, users and Regulators.